Bristol-Myers Squibb Company (BMY) Holdings Lifted by Family Management Corp

Family Management Corp raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 102.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,155 shares of the biopharmaceutical company’s stock after buying an additional 10,700 shares during the period. Family Management Corp’s holdings in Bristol-Myers Squibb were worth $1,179,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Connecticut Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth about $224,000. Birmingham Capital Management Co. Inc. AL increased its stake in shares of Bristol-Myers Squibb by 4.4% during the first quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock worth $3,860,000 after purchasing an additional 3,000 shares in the last quarter. HGK Asset Management Inc. increased its stake in shares of Bristol-Myers Squibb by 20.8% during the first quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock worth $16,794,000 after purchasing an additional 53,221 shares in the last quarter. Investment Partners Ltd. OH ADV increased its stake in shares of Bristol-Myers Squibb by 1.4% during the first quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock worth $1,107,000 after purchasing an additional 274 shares in the last quarter. Finally, Goelzer Investment Management Inc. increased its stake in shares of Bristol-Myers Squibb by 85.4% during the first quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock worth $4,100,000 after purchasing an additional 34,735 shares in the last quarter. 69.82% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company (BMY) opened at $63.47 on Thursday. The firm has a market cap of $103,570.38, a PE ratio of 21.38, a P/E/G ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.52%. Bristol-Myers Squibb’s payout ratio is presently 61.42%.

A number of analysts have recently commented on BMY shares. Jefferies Group reissued a “buy” rating and set a $66.00 target price (up previously from $63.00) on shares of Bristol-Myers Squibb in a research note on Thursday, August 24th. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price for the company. in a research note on Tuesday, August 22nd. Goldman Sachs Group reissued a “buy” rating and set a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. UBS reissued a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Finally, Citigroup boosted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $64.93.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (BMY) Holdings Lifted by Family Management Corp” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/14/bristol-myers-squibb-company-bmy-holdings-lifted-by-family-management-corp.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

What are top analysts saying about Bristol-Myers Squibb? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit